Better Health for All

iRhythm's core products and services, such as the Zio monitor and associated diagnostic services, are designed to detect, predict, and prevent cardiac arrhythmias, which are a leading cause of stroke and other serious outcomes.

This long-term continuous monitoring is 2x more likely to result in specified arrhythmia diagnoses compared to Holter monitoring and 2.6x greater for AF detection than usual care, leading to fewer ED visits, reduced hospital admissions, and improved patient outcomes. The company's mission is to boldly innovate to create trusted solutions that detect and prevent disease, and its products are described as delivering safe and effective cardiac monitoring. The company has expanded commercially into four European countries and received regulatory approval in Japan, increasing access to its services. It also offers discounted self-pay, financial assistance, and payment plans for patients with financial hardship. However, the FDA issued a warning letter on May 25, 2023, citing violations related to the Zio AT system, including failure to report at least two patient deaths within the required 30-day window and failure to report significant arrhythmias to doctors. The FDA also noted inadequate labeling regarding transmission limits and inaccessible patient data if registration was incomplete. The company has an Advancing Health Equity task force and Employee Resource Groups, but specific funding or reach metrics are not provided. During the COVID-19 crisis, iRhythm supported remote cardiac monitoring, reducing patient and staff exposure. The company also provides an Employee Assistance Program for mental health support and encourages employees with substance abuse problems to seek help.

Fair Money & Economic Opportunity

iRhythm Technologies, Inc. is a digital healthcare company focused on cardiac monitoring, not a financial institution.

Therefore, all KPIs related to lending, financial products, APRs, fees, and financial literacy are not applicable. The company does not offer lending or deposit services to consumers, nor does it generate or manage customer financial data. It does not provide debt products or operate financial service access points. While iRhythm aims to provide care irrespective of ability to pay and offers financial assistance, there is no specific data on the share of underserved clients in a financial context. Similarly, the MyZio app provides educational content related to medical conditions and device usage, not financial literacy. The company adheres to Medicare Independent Diagnostic Testing Facility (IDTF) Performance Standards, but this is not related to fair lending compliance for financial products. The Zio ECG monitors are designed for ease of use, with 91% of patients reporting it is easy to use, but this KPI is for financial product simplicity.

Fair Trade & Ethical Sourcing

No quantitative data relevant to iRhythm Technologies, Inc.'s fair trade and ethical sourcing practices was found in the provided articles. The documents primarily consist of financial reports (Form 10-K)

, codes of conduct , and policy statements (Conflict Minerals Policy , Modern Slavery Act statement ), which outline commitments and compliance programs but do not provide specific metrics for fair trade certification, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend.

Honest & Fair Business

iRhythm Technologies has a whistleblower policy that includes a non-retaliation policy, an Ethics Helpline (1-844-884-0117), and a web portal (irhythmethics.ethicspoint.com) for confidential reporting.

The company's anti-corruption policy includes a Code of Conduct, a Supplier Code of Conduct, and a commitment to compliance with the Foreign Corrupt Practices Act of 1977. However, in May 2023, the FDA issued a warning letter to the company, citing systemic failures in compliance, disclosure, and product safety regarding the Zio AT System. These failures included marketing beyond cleared use, unapproved modifications, and labeling violations, with two patient deaths linked to a defect. The company had received transmission limit complaints since 2019 but took no corrective action until 2023. Other issues included reused device components retaining prior patients' ECG data and miscalculation of device error risks. A class-action lawsuit was filed in 2024 alleging material misstatements and breaches of fiduciary duty by executives, with the court denying the company's motion to dismiss.

Kind to Animals

iRhythm Technologies, Inc. explicitly states that it conducts no animal testing as part of its products and activities.

This is confirmed by two separate articles. Given the company's focus on digital healthcare and wearable biosensors, there is no evidence of animal-derived products, animal husbandry, or animal agriculture operations, making several animal-related KPIs not applicable to its business model.

Planet-Friendly Business

iRhythm Technologies UK Ltd. reported 100% renewable electricity for its site in 2023.

For the broader company, 39.7% of electricity purchased at the Cypress facility in 2022 came from renewable sources. The company has a net-zero target year of 2045. The waste diversion rate was 89.5% in 2024, with 100% of waste diverted from landfill for iRhythm Technologies UK Ltd. in 2023. A life cycle analysis (LCA) has been conducted on products.

Zero Waste & Sustainable Products

The company achieved an 89.5% landfill waste diversion rate across its operations.

Circularity measures are embedded in the business model, focusing on component reuse and recycling, with the Zio Monitor being 72% smaller and 62% lighter than the previous generation, and using one coin-cell battery instead of two. Hazardous waste, including batteries, plastics, and circuit boards from returned devices, is recycled through partners, and printed material with Protected Health Information (PHI) is shredded and recycled. No waste disposal violations or citations were mentioned in the 2022 ESG report. The company aims to reduce material usage per device, as evidenced by the smaller Zio Monitor. The Cypress, CA manufacturing facility earned ISO 14001:2015 certification in 2024.